TEVA•benzinga•
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
Summary
Teva beat Q1 EPS estimates and raised 2025 profit guidance as Austedo sales soared and margins improved, despite missing revenue expectations.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 7, 2025 by benzinga